Etoposide in Langerhans cell histiocytosis in children: a preliminary experience

Pediatr Hematol Oncol. 1996 Mar-Apr;13(2):159-62. doi: 10.3109/08880019609030806.

Abstract

Treatment of Langerhans cell histiocytosis (LCH) is yet to be established. We treated seven patients with etoposide alone at a dose of 100 mg/m2/day for 3 days given every 3 to 4 weeks for six cycles. Three patients had received prior chemotherapy, two patients were less than 2 years of age, and two had liver dysfunction. A positive response to therapy was seen in five patients. There was no major toxicity. Etoposide therapy is safe and effective in the treatment of LCH.

MeSH terms

  • Antineoplastic Agents, Phytogenic / adverse effects
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Child
  • Child, Preschool
  • Etoposide / adverse effects
  • Etoposide / therapeutic use*
  • Female
  • Histiocytosis, Langerhans-Cell / drug therapy*
  • Humans
  • Infant
  • Male
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Etoposide